Table 1 Baseline characteristics and treatments of patients infected with SARS-CoV-2
Total (n = 310) | Nonhypertension (n = 197) | Hypertension (n = 113) | P value | |
|---|---|---|---|---|
Age, years | 62 (40–70) | 57 (40–68) | 67 (58–73) | <0.001 |
Sex | – | – | – | 0.395 |
Female | 136 (43.9%) | 90 (45.7%) | 46 (40.7%) | |
Male | 174 (56.1%) | 107 (54.3%) | 67 (69.3%) | |
Comorbidities | ||||
Constructive pulmonary disease | 9 (2.9%) | 6 (3.0%) | 3 (2.7%) | 1.000 |
Diabetes mellitus | 48 (15.5%) | 16 (8.1%) | 32 (28.3%) | <0.001 |
Cerebrovascular disease | 21 (6.8%) | 7 (3.6%) | 14 (12.4%) | 0.003 |
Cardiovascular disease | 19 (6.1%) | 11 (5.6%) | 8 (7.1%) | 0.597 |
Chronic liver disease | 4 (1.3%) | 2 (1.0%) | 2 (1.8%) | 0.965 |
Cancer | 1 (0.3%) | 1 (0.5%) | 0 (0.0%) | 1.000 |
Signs and Symptoms | ||||
Fever | 254 (81.9%) | 163 (82.7%) | 91 (80.5%) | 0.626 |
Cough | 196 (63.2%) | 133 (67.5%) | 63 (55.8%) | 0.039 |
Dyspnea | 162 (52.3%) | 93 (47.2%) | 69 (61.1%) | 0.019 |
Expectoration | 60 (19.4%) | 44 (22.3%) | 16 (14.2%) | 0.079 |
Muscle ache | 24 (7.7%) | 13 (6.6%) | 11 (9.7%) | 0.320 |
Diarrhea | 40 (12.9%) | 25 (12.7%) | 15 (13.3%) | 0.883 |
Headache | 3 (1.0%) | 2 (1.0%) | 1 (0.9%) | 1.000 |
Treatments and prognosis | ||||
Noninvasive mechanical ventilation | 37 (11.9%) | 21 (10.7%) | 16 (14.2%) | 0.360 |
Invasive mechanical ventilation | 34 (11.0%) | 15 (7.6%) | 19 (16.8%) | 0.013 |
ECMO | 5 (1.6%) | 1 (0.5%) | 4 (3.5%) | 0.116 |
ICU admission | 51 (16.5%) | 24 (12.2%) | 27 (23.9%) | 0.007 |
Duration of viral shedding after COVID-19 onset, days | 7 (5–12) | 8 (8–11) | 7 (5–13) | 0.144 |
Disease severity | – | – | – | |
Non-severe | 155 (50.0%) | 114 (57.9%) | 41 (36.3%) | |
Severe | 155 (50.0%) | 83 (42.1%) | 72 (63.7%) | <0.001 |
Death | 58 (18.7%) | 30 (15.2%) | 28 (24.8%) | 0.038 |
Hospitalization time, days | 17 (11–26) | 11 (10–23) | 11 (10–21) | 0.014 |
